Heat-labile Escherichia coli toxin enhances the induction of allergen-specific IgG antibodies in epicutaneous patch vaccination

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 72, Issue 1, 2017, Pages 164-168

  Cabauatan, C R ^a   Campana, R ^a   Niespodziana, K ^a   Reinisch, C ^b   Lundberg, U ^b   Meinke, A ^b   Henning, R ^c   Neubauer, A ^c   Valenta, R ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Valneva Austria GmbH   (Austria)

^c BIOMAY AG   (Austria)

Author keywords

allergen specific immunotherapy; epicutaneous allergen specific immunotherapy; heat labile Escherichia coli toxin; patch delivery system; rBet v 1

Indexed keywords

ALUMINUM HYDROXIDE; BACTERIAL TOXIN; HEAT LABILE TOXIN; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G ANTIBODY; POLLEN ANTIGEN; RBET V 1 ALLERGEN; RECOMBINANT ALLERGEN; UNCLASSIFIED DRUG; ALLERGEN; ENTEROTOXIN; ESCHERICHIA COLI PROTEIN; HEAT-LABILE ENTEROTOXIN, E COLI; IMMUNOGLOBULIN G; PLANT ANTIGEN; RECOMBINANT PROTEIN;

ANIMAL EXPERIMENT; ARTICLE; BIRCH; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG MEGADOSE; EPICUTANEOUS ALLERGEN SPECIFIC IMMUNOTHERAPY; ESCHERICHIA COLI; EXPERIMENTAL GUINEA PIG; FEMALE; IMMUNOTHERAPY; LOW DRUG DOSE; NONHUMAN; POLLEN ALLERGY; PRIORITY JOURNAL; SUBCUTANEOUS IMMUNOTHERAPY; VACCINATION; ANIMAL; ANTIBODY SPECIFICITY; BLOOD; DESENSITIZATION; GUINEA PIG; IMMUNIZATION; IMMUNOLOGY; PROCEDURES; TRANSDERMAL PATCH;

ALLERGENS; ANIMALS; ANTIBODY SPECIFICITY; ANTIGENS, PLANT; BACTERIAL TOXINS; DESENSITIZATION, IMMUNOLOGIC; ENTEROTOXINS; ESCHERICHIA COLI PROTEINS; FEMALE; GUINEA PIGS; IMMUNIZATION; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; RECOMBINANT PROTEINS; TRANSDERMAL PATCH; VACCINATION;

EID: 84990061237     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/all.13036     Document Type: Article

References (13)

1. Werfel T. Epicutaneous allergen administration: a novel approach for allergen-specific immunotherapy? J Allergy Clin Immunol 2009;124:1003–1004.
2. Senti G, von Moos S, Kundig TM. Epicutaneous immunotherapy for aeroallergen and food allergy. Curr Treat Options Allergy 2014;1:68–78.
3. Senti G, Graf N, Haug S, Ruedi N, von Moos S, Sonderegger T et al. Epicutaneous allergen administration as a novel method of allergen-specific immunotherapy. J Allergy Clin Immunol 2009;124:997–1002.
4. Senti G, von Moos S, Tay F, Graf N, Johansen P, Kundig TM. Determinants of efficacy and safety in epicutaneous allergen immunotherapy: summary of three clinical trials. Allergy 2015;70:707–710.
5. Dioszeghy V, Mondoulet L, Dhelft V, Ligouis M, Puteaux E, Benhamou PH et al. Epicutaneous immunotherapy results in rapid allergen uptake by dendritic cells through intact skin and downregulates the allergen-specific response in sensitized mice. J Immunology 2011;186:5629–5637.
6. Siebeneicher S, Reuter S, Krause M, Wangorsch A, Maxeiner J, Wolfheimer S et al. Epicutaneous immune modulation with Bet v 1 plus R848 suppresses allergic asthma in a murine model. Allergy 2014;69:328–337.
7. Larche M, Akdis CA, Valenta R. Immunological mechanisms of allergen-specific immunotherapy. Nat Rev Immunol 2006;6:761–771.
8. Frech SA, Dupont HL, Bourgeois AL, McKenzie R, Belkind-Gerson J, Figueroa JF et al. Use of a patch containing heat-labile toxin from Escherichia coli against travellers' diarrhoea: a phase II, randomised, double-blind, placebo-controlled field trial. Lancet 2008;371:2019–2025.
9. Pauli G, Larsen TH, Rak S, Horak F, Pastorello E, Valenta R et al. Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis. J Allergy Clin Immunol 2008;122:951–960.
10. Barbero AM, Frasch HF. Pig and guinea pig skin as surrogates for human in vitro penetration studies: a quantitative review. Toxico In Vitro 2009;23:1–13.
11. Fingerut E, Gutter B, Goldway M, Eliahoo D, Pitcovski J. B subunit of E. coli enterotoxin as adjuvant and carrier in oral and skin vaccination. Vet Immunol Immunopathol 2006;112:253–263.
12. Petrovska L, Lopes L, Simmons CP, Pizza M, Dougan G, Chain BM. Modulation of dendritic cell endocytosis and antigen processing pathways by Escherichia coli heat-labile enterotoxin and mutant derivatives. Vaccine 2003;21:1445–1454.
13. Vrtala S, Hirtenlehner K, Vangelista L, Pastore A, Eichler HG, Sperr WR et al. Conversion of the major birch pollen allergen, Bet v 1, into two nonanaphylactic T cell epitope-containing fragments: candidates for a novel form of specific immunotherapy. J Clin Invest 1997;99:1673–1681.